Our Board

His background provides him a wide understanding of business management and advocacy at all levels of industry and Government. John is currently Chairman of the Northern Co-operative Meat Company, a globally recognised farmer owned Co-operative. He is currently Chairman of the Co-operative Alliance in northern New South Wales and represents the industry at both State and national levels.

John has a strong rural focus and has a particular interest in rural health issues. After being diagnosed with a potentially life threating invasive form of squamous cell carcinoma whilst living in western NSW, John appreciates the importance of support and information for patients having difficulty accessing specialised treatment.

John has a Bachelor of Agricultural Science (UNE) and is a member of the Australian Institute of Company Directors.

Victoria has been a CEO, Director and Senior Strategist in the charity sector for fourteen years.

With a deep passion for social justice and consumer advocacy, Victoria has a special interest in health and achieving the best possible outcomes for those affected by melanoma.

Victoria enjoys working closely with Boards’ on business strategy, governance and risk, successful delivery of major contracts and projects, fundraising and financial diversification.

Victoria holds a Bachelor of Arts (Hons) degree in Economics and Law, post graduate diploma from the Chartered Institute of Marketing (UK) and Australian Institute of Company Directors, Company Directors Course.

Daniel has extensive professional experience in Private Equity and Strategy fields through his work as a management consultant with McKinsey & Co in Sydney and New York, CEO of Sands Group, and now Managing Director of Redwood North, a Private Equity and Real Estate Investment Firm.

Daniel has completed an MBA from Columbia Business School in New York, an LLB/ B.Com (Accounting) from Bond University, and is a Graduate of the Australian Institute of Company Directors.

She has experience in a range of clinical, policy, research, academic and senior management roles within health and social care, having worked in government, higher education, commercial and non-profit sectors in a career spanning over thirty years. Marie-Claire’s most recent previous roles include: National Clinical Director for 1800RESPECT, the national telephone and online counselling service for people impacted by sexual assault and domestic and family violence and Director of Support Programs for Prostate Cancer Foundation of Australia.

Marie-Claire is currently working as a consultant with health, human services and social care organisations in the areas of strategic planning, psychosocial program innovation and development, quality assurance and improvement. She also facilitates training and professional development in the areas of leadership and management in the health and social care sector. She is a previous National Vice-President of the Australian Association of Social Workers (2008 – 2011; 2016 – 2018). Marie-Claire is a 2012 Winston Churchill Fellow. Her research involved an overseas study of social work education and workforce planning in the United States, Canada, England and Denmark, exploring contemporary workforce needs and the readiness to practice of social work graduates.

• Fellow, Royal College of Surgeons of Edinburgh (Ad Hom) 2012
• Mayne Professor, Head of Discipline of Surgery, University of Queensland
• Director, Upper Gastro-intestinal and Soft Tissue Unit, Princess Alexandra Hospital.
• Chairman, Queensland Melanoma Project
• Director, Melanoma Patients Australia

Melanoma interests:
Surgeon involved in the management of patients with all stages of melanoma for 26 years.
Senior surgeon at the Melanoma Clinic at the Princess Alexandra Hospital

Research involvement:
Epidemiology of melanoma in Queensland – Collaboration with the Queensland Institute of Medical Research, Epidemiology Unit.
Assessment of the outcomes of patients with high risk primary and secondary melanoma.
Phase I-III trials in the surgical and medical management of patients with stage III and IV melanoma. These include locally based studies as well as collaboration in national and international trials.

She was subsequently diagnosed in mid-2013 at stage IV melanoma. She was treated with Keytruda as part of a trial from October 2013 to October 2015 and has shown no evidence of disease in regular scans since that time.